For research use only. Not for therapeutic Use.
Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].
Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3].
Halopemide (10 mg/kg; p.o.) induces dyskinesias in the majority of monkeys tested[2].
| Catalog Number | I011736 |
| CAS Number | 59831-65-1 |
| Synonyms | N-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide |
| Molecular Formula | C21H22ClFN4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H22ClFN4O2/c22-15-3-6-19-18(13-15)25-21(29)27(19)17-7-10-26(11-8-17)12-9-24-20(28)14-1-4-16(23)5-2-14/h1-6,13,17H,7-12H2,(H,24,28)(H,25,29) |
| InChIKey | NBHPRWLFLUBAIE-UHFFFAOYSA-N |
| SMILES | C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCNC(=O)C4=CC=C(C=C4)F |
| Reference | [1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. [2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the “antidyskinetic” drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. [3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839. |
